Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02220387
Other study ID # 01201463369/1
Secondary ID 01201463369
Status Completed
Phase N/A
First received August 11, 2014
Last updated October 5, 2015
Start date August 2014
Est. completion date September 2014

Study information

Verified date October 2015
Source Novosibirsk City Hospital #2
Contact n/a
Is FDA regulated No
Health authority Russia: The Ministry of Education and Science of the Russian Federation
Study type Observational

Clinical Trial Summary

The objective of this study is to investigate molecular, cytological and genetic features of occupational chronic obstructive pulmonary disease (COPD) in conditions of different occupational exposures. In order to achieve this goal serum pro-inflammatory cytokines and standard inflammation markers level, hemostasis, cytological analysis of bronchoalveolar lavage and associations of single nucleotide polymorphisms (SNPs) rs1800470 transforming growing factor β1 (TGF β1) gene, rs1828591 hedgehog interacting protein (HHIP) gene, rs4129267 interleukin 6 receptor (IL-6R) gene, rs1051730 nicotinic acetylcholine receptor 3 (CHRNA3) gene with COPD in subjects exposed to silica dust and in those exposed to polycyclic aromatic hydrocarbons exhaust will be investigated. The relationship between genotype and phenotype characteristics, such as an inflammation activity, assessed by C-reactive protein (hsCRP) and tumor necrosis factor-α (TNF α) serum concentration, in different occupational COPD groups will be studied. The hypothesis is that the mechanisms underlying disease development and progression are different due to environmental risk factor that reflex in differs in disease attributes - molecular biomarkers, cytology results and genetic susceptibility between COPD due to dust, COPD due to chemicals and COPD in smokers therefore COPD can be subdivided into ecological phenotypes according to environmental risk factor.


Description:

Study rationale: The main risk factors of COPD are tobacco smoking, biomass smoking and occupational factors. Tobacco smoking is well-known risk factor so tobacco induced COPD is completely established. Nevertheless the meaning of occupational factors which are less famous are equally important. Based on comprehensive literature review American Thoracic Society (ATS) endorsed the notion that strong evidence implicates occupational factors as cause of COPD [Eisner MD et al., 2010]. Occupational COPD takes 19.2 % of all COPD patients and 31.1 % of never smokers as resulted NHANESIII study [Hnizdo E. et al., 2004]. A considerable number of work-related factors have evidence for a causal association with COPD including (and of course not limited) silica and silicates and polycyclic aromatic hydrocarbons. Individuals in a variety of occupations and industries such as coal miners, coke workers, tunnel workers, metallurgists, welding workers, transportation workers, builders, farmers are exposed to factors cited above. Despite this the clinical and pathophysiological features of COPD caused by occupational factors are still unclear.

Occupational factors leading airflow limitation are various entities - vapors, dusts, gases and fumes with different physical, chemical, biological and other features, so the mechanisms underlying disease development and progression may be different attributable to risk factor.

An environmental risk factors exposure as well as tobacco smoking results in COPD only in part of the subjects which indicates the significant genome and gene environmental interactions role. COPD develops in predisposed subjects undergoing risk factors exposure. Therefore the risk of COPD is individual and depends on both genetic and environments. There are few data concerning the effects of genetic on COPD risk in this specific subgroup - people who are exposed to occupational risk factors related to the certain environmental factor.

Statistical analysis: Statistical analysis will be carried out by Statistica 9.0 software. Significance level will be considered p = 0.05. The qualitative variables will be expressed as counts and percentages. The quantitative continuous variables will be expressed as means and standard error of means (M ± m) for variables that meet the criteria of normality and minimum and maximum, median for those that do not meet the criteria of normality. Kruskal-Wallis test will be used for comparing multiply independent samples and Mann-Whitney U test for comparing two independent samples if variable under consideration will continuous and that it will be measured on an ordinal scale. For comparisons of proportions, the Chi-square will be used.

For associations assessment logistic regression method will be used. The odds ratio (OR) and 95% confidence interval (CI) will be calculated for each professional group. Multiple regression model will be used to explore the relationships between demographic characteristics, cytokine concentrations, hemostasis and airflow limitation in professional groups.


Recruitment information / eligibility

Status Completed
Enrollment 352
Est. completion date September 2014
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Male
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria:

- Post- bronchodilator forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio less than 0.7

- Stable phase of COPD

- History of exposure to respirable silica dust, nonsmokers with absence of passive exposure to tobacco smoke or history of exposure to polycyclic aromatic hydrocarbons exhaust, nonsmokers with absence of passive exposure to tobacco smoke or current tobacco smokers without history of occupational exposure

- COPD risk factor exposure (occupational or tobacco smoke) duration not less than 12 months

- Male

- Caucasian

- Age of 40 - 75 years old

- Control group - healthy people

Exclusion Criteria:

- history of biomass smoke exposure

- age less than 40 and above 75 years old

- current COPD exacerbation

- concomitant asthma

- tuberculosis and other pulmonary diseases

- allergic and autoimmune disorders

- active infections

- immunodeficiency, including HIV infection

- parasitological diseases

- malignancies

- lack of informed consent

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Intervention

Other:
exposure to respirable silica dust
History of exposure to respirable silica dust due to job
exposure to polycyclic aromatic hydrocarbons exhaust
history of exposure to polycyclic aromatic hydrocarbons exhaust due to job

Locations

Country Name City State
Russian Federation Novosibirsk City Hospital #2 Novosibirsk

Sponsors (2)

Lead Sponsor Collaborator
Novosibirsk City Hospital #2 Siberian Branch of the Russian Academy of Medical Sciences

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Association of SNPs rs1800470 TGF ß1 gene, rs1828591 HHIP gene, rs4129267 IL-6R gene, rs1051730 CHRNA3 gene with COPD in subjects exposed to dust and in those exposed to chemicals. Odds ratio and 95% confidence interval will be calculated for each occupational group. Controls - healthy people. 1 day (a single measurement) No
Primary Difference in cytological analysis of bronchoalveolar lavage fluid results between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Primary Difference in serum interleukin 1 beta (IL-1ß) level between COPD patients exposed to dust, chemicals and tobacco smoke. Comparison of groups. 1 day (a single measurement) No
Primary Difference in serum TNFa level between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Primary Difference in spontaneous thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Primary Difference in collagen induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Primary Difference in epinephrine induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Primary Difference in adenosine diphosphate induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Primary Difference in fibrinogen level between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Primary Difference in fibrinogen degradation products level between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Primary Difference in D-dimer level between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Primary Difference in serum endothelin1 level between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Primary Difference in serum nitric oxide level between COPD patients exposed to dust, chemicals and tobacco smoke Comparison of groups. 1 day (a single measurement) No
Secondary Relationship between genotype and phenotype characteristics, such as an inflammation activity, assessed by hsCRP and TNF a serum concentration, in different occupational COPD groups. For SNPs that will occur associated with occupational COPD differences in hsCRP and TNFa serum concentration between subjects with different genotypes will be established separately for exposed to dust COPD group and for exposed to chemicals COPD group. 1 day (a single measurement) No
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy